All In Biotech

Drug Trial Radar · NCT06799520

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 17, 2025

Primary completion

Oct 19, 2026

Study completion Feb 19, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Alopecia Areata (AA)
  • Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)

Interventions

  • VIS171Drug

    VIS171 will be administered as a SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) Graded by SeverityTime frame: From first dose of the study drug up to end of the study (up to Week 45)

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Visterra Investigational Site

    Sofia, Bulgaria

  • Visterra Investigational Site

    Chisinau, Moldova

  • Visterra Investigational Site

    Bucharest, Romania

  • Visterra Investigational Site

    Cluj-Napoca, Romania

  • Visterra Investigational Site

    Barcelona, Spain

  • Visterra Investigational Site

    Granada, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.